Skip to content

    3B Blackbio Dx Limited

    Healthcare
    Healthcare
    ₹1,196.1
    -4.06% from avg

    Overview

    Price

    ₹1,196.1

    Market Cap

    ₹1.1k Cr

    Sector

    Healthcare

    Healthcare

    Rank

    4

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital77799999
    Reserves131516188219264290310
    Borrowings42321000
    Other Liabilities4451621244231
    Total Liabilities282932214250297341350
    AssetsFixed Assets223776177
    CWIP00000000
    Investments444102128167160188
    Other Assets222325105116124163155
    Total Assets282932214250297341350

    Cash Flow

    Cash Flow

    ₹ Cr · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25FY26
    ActivitiesCash from Operating013821284443
    Cash from Investing0-20-2-8-20-34-20
    Cash from Financing01-2-6-3-4-3-7
    SummaryCapital Expenditure
    Free Cash Flow013620284441
    FCF Margin

    Valuation

    Assumptions

    Current — 3BBLACKBIO
    Price
    ₹1,196
    EPS (TTM)
    ₹57.46
    PE (TTM)
    20.8
    Profit growth
    20.0%

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (23.6×) and current (20.8×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹1,196
    vs
    Fair value · 15% return
    ₹1,352
    13%Undervalued

    At 20% growth and a 21× exit, ₹1196 only delivers your return if you pay ₹1,352. The price is currently baking in 17% growth.

    EPS grows 20%/yr for 5 years, then fades to 6% over 2, exits at 21×.

    YearGrowthEPS (₹)
    FY2720.0%68.95
    FY2820.0%82.74
    FY2920.0%99.29
    FY3020.0%119.15
    FY3120.0%142.98
    FY3213.0% ·fade161.57
    FY336.0% ·fade171.26

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse 3B Blackbio Dx Limited

    Guides on how to read this kind of business and the numbers that matter.